203 Core Drugs Flashcards
Core Drug : Insulin What class of drug? Mechanism? Indication? Side effects?
Indication - Diabetes mellitus
Insulin lowers blood glucose by stimulating peripheral glucose uptake primarily by skeletal muscle cells and fat, and by inhibiting glucose production and release by the liver.
Indication - Diabetes (Net effect is to cause hypoglycemia and increase fuel storage in muscle, fat tissue and liver), also Diabetic ketoacidosis (DKA)
Side effects - Hypoglycemia may occur
Short acting Insulin
Short-acting insulin begins to lower blood glucose levels within 30 minutes, so you need to have your injection 30 minutes before eating. It has its maximum effect two to five hours after injection and lasts for six to eight hours.
Long acting Insulin
Long acting insulins will be injected either once or twice daily
Mixed Insulin
Mixed or combination insulins are where a shorter acting insulin is combined with a longer acting insulin. On the plus side, this can mean less injections and can help to make dosages simpler.
Core Drug : Gliclazide What class of drug? Mechanism? Indication? Side effects?
Gliclazide is a type of medicine known as a sulfonylurea - it increases the amount of insulin that your pancreas makes
Gliclazide is a medicine used to treat type 2 diabetes
Primary mechanism of action- stimulates endogenous insulin release
Are Sulfonylureas orally active?
All orally active
All bound to plasma protein (90-99%)
Primary mechanism of action of sulfonylureas
stimulates endogenous insulin release
Core Drug : Metformin
What class of drug?
Mechanism?
Indication?
Biguanides
Metformin - oral antihyperglycemic
Biguanides do not stimulate insulin release or cause hypoglycemia - biguanides appear to increase glucose uptake in muscle and decrease glucose production by liver.
- The exact mechanism is unknown but does involve primarily suppression of hepatic glucose production through gluconeogenesis
- Increases insulin sensitivity
- Enhances peripheral glucose uptake
- Increases fatty acid oxidation via decreasing insulin-induced suppression of fatty acid oxidation
- Decreases glucose absorption from GI tract
Mechanism of action of Biguanides
The exact mechanism is unknown but does involve primarily suppression of hepatic glucose production through gluconeogenesis
- Increases insulin sensitivity
- Enhances peripheral glucose uptake
- Increases fatty acid oxidation via decreasing insulin-induced suppression of fatty acid oxidation
- Decreases glucose absorption from GI tract
What drugs increase insulin sensitivity
metformin - Biguanides
Core Drug : Pioglitazone
What class of drug?
Mechanism?
Indication?
Glitazones (thiazolidinediones)
Pioglitazone now only one remaining approved
Activate peroxisome proliferator-activated receptor-y(PPARy)
In presence of endogenous or exogenous insulin glitazones will
Decrease gluconeogenesis, glucose output, and triglyceride production in liver
Increase glucose uptake and utilization in skeletal muscle
Increase glucose uptake and decrease fatty acid output in adipose tissue
Cause differentiation of adipocytes
Monotherapy or with other anti-diabetic medications
Used for T2 diabetes - Type 2 diabetes mellitus (alone or combined with metformin or a sulfonylurea, or with both, or with insulin)
Adverse effects and toxicity of biguanides (e.g. metformin)
metformin produces lactic acidemia only rarely
more frequent in patients with renal impairment
nausea, abdominal discomfort, diarrhea, metallic taste, anorexia more common
vitamin B12 and folate absorption decreased with chronic metformin
myocardial infarction or septicemia mandate immediate stoppage (associated renal dysfunction)
Metformin contraindications
hepatic disease
past history of lactic acidosis (any cause)
cardiac failure
chronic hypoxic lung disease - causes metabolic acidosis
Glitazones (thiazolidinediones) - example
Pioglitazone - now only one remaining approved
Adverse effects and drug interactions - Glitazones
fluid retention (promotes amiloride-sensitive sodium ion reabsorption in renal collecting ducts) causing, edema, mild anemia dose-related weight gain safety in pregnancy and lactation not determined do not cause lactic acidosis, even in patients with renal impairment Liver damage may require regular blood tests Pioglitazone subject to interactions due to liver metabolism - may lower oral contraceptives levels containing ethinyl estradiol and norethindrone
Core Drug : Levothyroxine What class of drug? Mechanism? Indication? Adverse effects?
Levothyroxine is used to treat thyroid deficiency. It can be used to suppress TSH secretion in the treatment of some thyroid tumours. It can be given by mouth or by injection.
Adverse effects
At excessive doses: palpitations, arrhythmias, diarrhoea, insomnia, tremor, weight loss.
Levothyroxine
Levothyroxine is used to treat thyroid deficiency. It can be used to suppress TSH secretion in the treatment of some thyroid tumours. It can be given by mouth or by injection.
Oral Bioavailability - 100%
Protein binding - > 99% Metabolism = Metabolised in liver by glucoronidation
Half-life - 7 days approx
Excretion- 20-40% excreted in urine
Standard maintenance dose: 50-100 μg/day
Core Drug : Carbimazole What class of drug? Mechanism? Indication? Adverse effects?
Carbimazole is used to treat hyperthyroidism. Carbimazole is a pro-drug, after absorption it is converted to the active form, methimazole which prevents peroxidase iodinating the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4.
Adverse effects
Rashes and pruritus are common which can often be treated with antihistamines. The most serious rare side effect is neutropenia and agranulocytosis. Teratogenic.
Core Drug : Propylthiouracil What class of drug? Mechanism? Indication? Adverse effects?
Propylthiouracil (PTU) is used to treat hyperthyroidism (including Graves’ disease) by inhibiting thyroperoxidase, which normally acts in thyroid hormone synthesis. PTU also acts by inhibiting tetraiodothyronine deiodinase which converts T4 to T3. Drug of choice to treat hyperthyroidism in first trimester.
Adverse effects
Rashes and pruritus are common which can often be treated with antihistamines. Its notable side effects include a risk of agranulocytosis and risk of serious liver injury, including liver failure and death.
Which antithyroid drug is teratogenic?
carbimazole
Combined hormonal contraceptives (CHC)
Available as tablets (COC), transdermal patches (CTP), and vaginal rings (CVR).
Highly user-dependant methods where the failure rate if used perfectly (i.e. correctly and consistently) is less than 1%.
Certain factors such as the person’s weight, malabsorption including diarrhoea and vomiting (COC only), and drug interactions (enzyme inducing drugs) may contribute to contraceptive failure.
Prescriptions of up to 12 months’ supply for CHC initiation or continuation may be appropriate to avoid unwanted discontinuation and increased risk of pregnancy.
Should not be continued beyond 50 years of age as safer alternatives exist.
Benefits of Combined Hormonal Contraception
Reduced risk of ovarian, endometrial and colorectal cancer;
• Predictable bleeding patterns
• Reduced dysmenorrhoea and menorrhagia;
• Management of symptoms of polycystic ovary syndrome (PCOS), endometriosis and premenstrual syndrome;
• Improvement of acne;
• Reduced menopausal symptoms;
• Maintaining bone mineral density in peri-menopausal females under the age of 50 years.
Risks with Combined Hormonal Contraception
Breast cancer and cervical cancer associated with current or recent use of CHC is
small, but is greater than that with progestogen-only or non-hormonal contraception.
Venous and arterial thromboembolism
CHC is associated with a 3- to 3.5-fold increase in VTE risk compared with non-use of CHC.
Absolute risk of VTE during use of CHC is estimated by the European Medicines Agency to be between 5 and 12 per 10 000 women per year of use compared to 2 per 10 000 non-CHC users per year.
NB VTE risk is lower during CHC use than during pregnancy and the postpartum period.214–221 By reducing rates of unplanned pregnancy, CHC use lowers the overall rate of VTE in the population in comparison to populations without access to effective contraception.
VTE events that do occur during use of CHC, approximately 1% are fatal
n Levonorgestrel (LNG), norethisterone (NET) and norgestimate COC are associated with a lower risk of venous thromboembolic events than COC containing newer progestogens, the combined transdermal patch and the combined vaginal ring.
COC containing higher EE (ethinylestradiol) doses may be associated with greater risk of arterial thrombotic events than lower EE doses.
Oral progestogen-only contraceptives
Alter cervical mucus to prevent sperm penetration and may inhibit ovulation in some women;
oral desogestrel-only preparations consistently inhibit ovulation and this is their primary mechanism of action.
Progestogen-only contraceptives offer a suitable alternative to combined hormonal contraceptives when oestrogens are contra- indicated.